1,6-萘啶-2-甲腈 | 852930-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,6-萘啶-2-甲腈
• 英文名称: 2-Cyan-1,6-naphthyridin
• 英文别名: [1,6]naphthyridine-2-carbonitrile；1,6-Naphthyridine-2-carbonitrile
• CAS: 852930-87-1
• 化学式: C₉H₅N₃
• mdl: MFCD03644617
• 分子量: 155.159
• InChiKey: AXNYSDICQDNOOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,6-萘啶-2-甲腈 在 羟胺 、 碳酸氢钠 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors

  摘要：

  The Hedgehog (Hh-) signalling pathway is a key developmental pathway and there is a growing body of evidence showing that this pathway is aberrantly reactivated in a number of human tumors. Novel agents capable of inhibiting this pathway are sought, and an entirely novel series of smoothened (Smo) antagonists capable of inhibiting the pathway have been identified through uHTS screening. Extensive exploration of the scaffold identified the key functionalities necessary for potency, enabling potent nanomolar Smo antagonists like 91 and 94 to be developed. Optimization resulted in the most advanced compounds displaying low serum shift, clean off-targets profile, and moderate clearance in both rats and dogs. These compounds are valuable tools with which to probe the biology of the Hh-pathway. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.031

文献信息

• [EN] TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] TÉTRAHYDRONAPHTHYRIDINES ET SES DÉRIVÉS AZA À TITRE D'ANTAGONISTES DES RÉCEPTEURS D'HISTAMINE H3
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009121812A1

  公开（公告）日：2009-10-08

  The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中X1a，X1至X5，Ra，Rb，n和R的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及药物组合物，以及制备此类化合物的方法，以及作为药物的生产和使用。
• HYDRAZINO-SUBSTITUTED HETEROCYCLIC NITRILE COMPOUNDS AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1739081A1

  公开（公告）日：2007-01-03

  A compound having an inhibitory activity against cysteine protease, represented by formula (I): (wherein ring X is a heterocyclic group which may contain 1 to 4 hetero atoms selected from an nitrogen atom(s), a oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to said nitrogen atom in the ring; J is a bond or a spacer having from 1 to 8 atoms; R, R1, R2 and R3 is each independently hydrogen atom or a substituent; n is 0 or an integer of 1 to 10), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof; and an agent for prevention and/or treatment for a cysteine protease-related disease, such as osteoporosis, comprising it as an active ingredient are provided.

  一种对半胱氨酸蛋白酶具有抑制活性的化合物，由式 (I) 表示： (其中环 X 是杂环基团，除了环中的所述氮原子外，还可包含 1 至 4 个选自氮原子、氧原子和可被氧化的硫原子的杂原子；J 是具有 1 至 8 个原子的键或间隔物；R、R1、R2 和 R3 各自独立地是氢原子或取代基；n为0或1至10的整数）、其盐、其溶液或其N-氧化物或其原药；以及包含其作为活性成分的用于预防和/或治疗半胱氨酸蛋白酶相关疾病（如骨质疏松症）的制剂。
• TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS
  申请人：Evotec AG

  公开号：EP2268638A1

  公开（公告）日：2011-01-05
• Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors
  作者：Jesus M. Ontoria、Laura Llauger Bufi、Caterina Torrisi、Alberto Bresciani、Claudia Giomini、Michael Rowley、Sergio Serafini、Hu Bin、Wu Hao、Christian Steinkühler、Philip Jones

  DOI：10.1016/j.bmcl.2011.07.031

  日期：2011.9

  The Hedgehog (Hh-) signalling pathway is a key developmental pathway and there is a growing body of evidence showing that this pathway is aberrantly reactivated in a number of human tumors. Novel agents capable of inhibiting this pathway are sought, and an entirely novel series of smoothened (Smo) antagonists capable of inhibiting the pathway have been identified through uHTS screening. Extensive exploration of the scaffold identified the key functionalities necessary for potency, enabling potent nanomolar Smo antagonists like 91 and 94 to be developed. Optimization resulted in the most advanced compounds displaying low serum shift, clean off-targets profile, and moderate clearance in both rats and dogs. These compounds are valuable tools with which to probe the biology of the Hh-pathway. (C) 2011 Elsevier Ltd. All rights reserved.